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https://doi.org/10.1016/j.stemcr.2018.01.002SUMMARYNon-human primates (NHPs) can serve as a human-like model to study cell therapy using induced pluripotent stem cell-derived
cardiomyocytes (iPSC-CMs). However, whether the efficacy of NHP and human iPSC-CMs is mechanistically similar remains unknown.
To examine this, RNU rats received intramyocardial injection of 1 3 107 NHP or human iPSC-CMs or the same number of respective
fibroblasts or PBS control (n = 9–14/group) at 4 days after 60-min coronary artery occlusion-reperfusion. Cardiac function and left
ventricular remodeling were similarly improved in both iPSC-CM-treated groups. To mimic the ischemic environment in the infarcted
heart, both culturedNHP andhuman iPSC-CMs underwent 24-hr hypoxia in vitro. Both cells andmediawere collected, and similarities in
transcriptomic as well as metabolomic profiles were noted between both groups. In conclusion, both NHP and human iPSC-CMs confer
similar cardioprotection in a rodent myocardial infarction model through relatively similar mechanisms via promotion of cell survival,
angiogenesis, and inhibition of hypertrophy and fibrosis.INTRODUCTION
With the recent progress in effective preventions and
advanced treatments, mortality rates for heart failure
and acute myocardial infarction (MI) have declined. How-
ever, 1 in every 4 deaths is still caused by heart disease
in the United States (Vos et al., 2012). Despite early phar-
macologic and medical device intervention to reduce
myocardial loss after infarction, viable cardiomyocytes
(CMs) within the ischemic zone and adjacent areas still
experience increased workload and metabolic stress, re-
sulting in heart failure with further cell loss and patho-
logic myocardial remodeling (Pfeffer and Braunwald,
1990).
In recent years, stem cell-based regenerative therapy
has entered preclinical and clinical trials to repair the
infarcted heart (Laflamme et al., 2007; Mangi et al.,
2003; Menasche´ et al., 2015, 2018). The unique proper-
ties of induced pluripotent stem cells (iPSCs), including
their ability for self-renewal, provide a sufficient resource
to generate differentiated cells for transplantation.
Although preclinical studies have shown that CMs differ-
entiated from iPSCs can improve cardiac function and
attenuate myocardial remodeling after MI (Carpenter
et al., 2012; Citro et al., 2014), the field is still mainly422 Stem Cell Reports j Vol. 10 j 422–435 j February 13, 2018 j ª 2018 The
This is an open access article under the CC BY license (http://creativecommoat the preclinical trial stage due to technical and practical
reasons (Neofytou et al., 2015). It is important to
examine the safety and immunogenicity further in a hu-
man-like animal model, such as non-human primates
(NHPs). NHPs have phylogenetic proximity to humans
and can be an ideal model for preclinical autologous/
allogeneic transplantation studies. However, an essential
step before NHP trials is to prove the equivalence of
functional efficacies and underlying therapeutic mecha-
nisms between NHP iPSC-CMs and human iPSC-CMs.
This step is necessary to translate NHP animal results to
clinical studies.
In the present study, we injected NHP iPSC-CMs or
human iPSC-CMs intramyocardially in a subacute MI rat
model. Four weeks after cell injection, similar improve-
ments in left ventricular (LV) function and myocardial re-
modeling were noted in both cell-treated groups, but not
in the control groups treated with PBS or NHP fibroblasts
or human fibroblasts. We further examined the effects of
oxygen depletion on NHP iPSC-CMs and human iPSC-
CMs in vitro, which is a condition the cells first encounter
after injection into the heart. The majority of the changes
in transcriptomic and metabolomic profile of NHP and
human iPSC-CMs were similar, with some species-specific
differences.Authors.
ns.org/licenses/by/4.0/).
Figure 1. Cardiac Function Assessment after Cell Injection
Echocardiography was monitored at 1 day before cell injection, and 2 weeks and 4 weeks after cell injection.
(A and B) LV ejection fraction (A) and fractional shortening (B) were improved significantly in both NHP and human iPSC-CM groups
compared with the PBS group.
(legend continued on next page)
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RESULTS
CMDifferentiation fromNHP iPSCs andHuman iPSCs
Thirty days after differentiation, silencing of reprogram-
ming factors were confirmed by qPCR in both NHP and
human iPSC-CMs (data not shown). Immunohistological
staining showed that both NHP and human iPSC-CMs ex-
pressed key cardiac markers such as cardiac troponin T
(cTnT) and a-actinin. In addition, the sarcomere structure
was clear and well aligned in both NHP and human iPSC-
CMs (Figure S1A), confirming successful differentiation.
Both NHP and human iPSC-CMs showed cardiac-specific
electrophysiological phenotype by displaying the three
subtypes of cardiac action potential: ventricular-like,
atrial-like, and nodal-like (Figure S1B and Table S1).Left Ventricular Function Change after Cell Injection
One day before cell injection, post-MI cardiac function was
assessed by echocardiography (Table S2). The rats were
divided into five groups to receive PBS, NHP fibroblasts,
NHP iPSC-CMs, human fibroblasts, or human iPSC-CMs.
Four weeks after injection, the left ventricular ejection frac-
tion (LVEF) did not change significantly in the PBS group
(0.7% ± 1.4%) or fibroblast control groups (0.6% ±
3.8% in NHP fibroblast group; +1.2% ± 2.8% in human
fibroblast group) but was increased significantly in both
the NHP iPSC-CM group (+13.3% ± 1.9%) and the human
iPSC-CM group (+11.3% ± 2.6%) ( p < 0.01, Figure 1A).
Similarly, fractional shortening was also significantly
improved in both cell-treated groups (+9.2% ± 1.5% in
NHP iPSC-CM group and +7.9% ± 1.8% in human iPSC-
CM group versus 0.1% ± 0.9% in PBS group, 0.0% ±
2.2% inNHP fibroblast group, and +1.2% ± 1.6% in human
fibroblast group; p < 0.01, Figure 1B). The improved
contractility was accompanied by the amelioration of LV
chamber dilatation at both phases of end-diastole (+27 ±
5.9 mL in NHP iPSC-CM group and +24 ± 7.9 mL in human
iPSC-CM group versus +48 ± 7.9 mL in PBS group, +65 ±
25 mL in NHP fibroblast group, and +126 ± 15 mL in human
fibroblast group; p < 0.05, Figure 1C) and end-systole
(14 ± 5.4 mL in NHP iPSC-CM group and 9.3 ± 9.4 mL(C) LV end-diastolic volume was markedly dilated in the PBS control, N
and human iPSC-CM groups.
(D) LV end-systolic volume was increased in the PBS control, NHP fibr
human iPSC-CM groups (n = 14 independent experiments). Hemodyna
(E) Examples of changes in pressure-volume relationships during infe
(F) Slope of end-systolic pressure-volume relationship (ESPVR) show
human iPSC-CM groups.
PBS, n = 7; NHP fibroblast, n = 9; NHP iPSC-CM, n = 11; human fibrobla
presented as mean ± SEM. **p < 0.01, NHP iPSC-CM versus NHP fibrobla
iPSC-CM versus human fibroblast; zzp < 0.01, human iPSC-CM versus P
424 Stem Cell Reports j Vol. 10 j 422–435 j February 13, 2018in human iPSC-CM group versus +28 ± 6.7 mL in PBS
group, +48 ± 21 mL in NHP fibroblast group, and +77 ±
12 mL in human fibroblast group; p < 0.05, Figure 1D)
compared with the baseline.
Hemodynamic analysis further confirmed the improve-
ment of LV systolic and diastolic function in both NHP
and human iPSC-CM-treated groups. With a similar heart
rate, LV systolic pressure, and LV systemic pressure, we
found that the maximum dP/dt was significantly higher
in both NHP iPSC-CM (7,497 ± 316 mmHg/s, n = 11) and
human iPSC-CM groups (7,991 ± 434 mmHg/s, n = 12)
compared with the NHP fibroblast (5,835 ± 242 mmHg/s,
n = 9), human fibroblast (6,385 ± 259 mmHg/s, n = 9),
and PBS control groups (6,628 ± 103 mmHg/s, n = 7;
p < 0.05) (Table S3). The slope of end-systolic pressure-vol-
ume relationship generated by inferior vena cava occlusion
suggests a similarly increased contractility in both NHP
iPSC-CM and human iPSC-CM groups compared with
both NHP and human fibroblast-treated groups as well as
the PBS-treated group (p < 0.01, Figures 1E and 1F). The
LV minimum dP/dt was lower in both NHP iPSC-CM
(6,393 ± 385 mmHg/s) and human iPSC-CM groups
(6,740 ± 499 mmHg/s) compared with NHP fibroblast
(5,357 ± 333 mmHg/s) and human fibroblast groups
(5,633 ± 196 mmHg/s), as well as the PBS group
(5,327 ± 101 mmHg) (p < 0.05, Table S3). The end-
diastolic pressure and time constant, tau, in both cell-
treated groups were similar and were significantly
decreased compared with both fibroblast groups or PBS
group (p < 0.05, Table S3).Reduced Infarct Size and Increased Viable
Myocardium in Cell-Treated Groups
Four weeks after cell transplantation, graft survival was
identified in the ischemic zone at different sections of the
left ventricle in both NHP and human iPSC-CM groups as
assessed by cTnTand human specific mitochondria double
staining (Figures 2A and 2B). The graft resulted in an
increased amount of viable tissue within the infarct
zone in both NHP iPSC-CM (39% ± 3.2%) and human
iPSC-CM groups (41% ± 3.2%) compared with the NHPHP fibroblast, and human fibroblast groups compared with both NHP
oblast, and human fibroblast groups but decreased in both NHP and
mics was analyzed using pressure-volume Millar catheter.
rior vena cava occlusion.
ed significantly preserved cardiac contractility in both NHP and
st, n = 9; human iPSC-CM, n = 12 independent experiments. Data are
st; ##p < 0.01, NHP iPSC-CM versus PBS; yp < 0.05, yyp < 0.01, human
BS; by one-way ANOVA.
(legend on next page)
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fibroblast (21% ± 1.2%) and human fibroblast groups
(24% ± 0.7%), as well as the PBS group (18% ± 1.1%;
p < 0.05) (Figures 2C and 2D). Additionally, the infarct
size was significantly smaller in the groups treated with
NHP iPSC-CMs (16% ± 1.1%) and human iPSC-CMs
(15% ± 1.1%) than that treated with NHP fibroblast
(22% ± 1.7%), human fibroblast (21% ± 1.7%), and PBS
(20% ± 0.8%; p < 0.05) (Figure 2E).
Attenuated Myocardial Remodeling with Increased
Angiogenesis after CM Transplantation
With the improvement in LV function and more viable tis-
sue in cell-treated groups, the extent of myocardial remod-
eling was further assessed at both the border zone (BZ) and
remote zone (RZ) of the infarct site according to the histol-
ogy approach. The endogenous rat cardiomyocytes were
significantly smaller in the groups treated with NHP iPSC-
CMs (393 ± 36 mm2 at BZ and 343 ± 21 mm2 at RZ) or human
iPSC-CMs (381 ± 29 mm2 at BZ and 343 ± 21 mm2 at RZ)
compared with PBS group (579 ± 69 mm2 at BZ and 505 ±
40 mm2 at RZ), NHP fibroblast group (552 ± 25 mm2 at BZ
and 413 ± 25 mm2 at RZ), and human fibroblast group
(524 ± 31 mm2 at BZ and 391 ± 24 mm2 at RZ), suggesting
a more limited hypertrophy (p < 0.05, Figures 3A and 3B).
A similar reduction of cardiac fibrosis was noted in both
cell-treated groups (16% ± 0.8% at BZ and 11% ± 0.4% at
RZ in the NHP iPSC-CM group, 16% ± 1.0% at BZ and
12% ± 0.5% at RZ in the human iPSC-CM group), but not
in control groups (20% ± 0.9% at BZ and 15% ± 0.9% at
RZ in PBS group, 18% ± 1.2% at BZ and 15% ± 1.0% at RZ
in NHP fibroblast group, 20% ± 1.1% at BZ and 15% ±
0.9% at RZ in human fibroblast group) (p < 0.05; Figures
3C and 3D). In addition to the attenuation of the myocar-
dial remodeling, the capillary density in both NHP iPSC-
CM (1,672 ± 110/mm2 at BZ and 2,387 ± 205/mm2 at RZ)
and human iPSC-CM groups (1,795 ± 130/mm2 at BZ and
2,475 ± 170/mm2 at RZ) were significantly higher than
those in the NHP fibroblast group (1,199 ± 88/mm2 at BZ
and 1,840 ± 109/mm2 at RZ), human fibroblast group
(1,158 ± 120/mm2 at BZ and 1,889 ± 161/mm2 at RZ),
and PBS group (1,163 ± 109/mm2 at BZ and 1,665 ±Figure 2. Graft and Scar Size Assessment at 4 Weeks after Myoca
(A) Examples of viable graft in the ischemic zone. Both NHP and huma
human specific mitochondria at 43 magnification.
(B) Viable grafts in both groups of iPSC-CM-treated hearts were obser
(C) Representative pictures of infarcted left ventricle with trichrome s
infarction than iPSC-CM-treated groups, which had more viable myoc
(D) The amount of viable myocardium was quantified within the ischem
(E) Scar size, presented as a percentage of fibrotic tissue to whole m
PBS, n = 5; NHP fibroblast, n = 6; NHP iPSC-CM, n = 6; human fibrob
are presented as mean ± SEM. *p < 0.05, **p < 0.01, NHP iPSC-CM ve
yyp < 0.01, human iPSC-CM versus human fibroblast; zzp < 0.01, huma
426 Stem Cell Reports j Vol. 10 j 422–435 j February 13, 2018136/mm2 at RZ) (p < 0.01; Figures 3E and 3F), indicating a
possible increase in angiogenesis and a reduction in cellular
remodeling/hypertrophy.
Gene Profile Change in Response to Oxygen Depletion
In Vitro
When transplanted, exogenous cells initially encounter the
hypoxic environment of the ischemic heart. To study their
responses to hypoxic condition, we next subjected cultured
NHP iPSC-CMs and human iPSC-CMs to oxygen depletion
for 24 hr. RNA sequencing (RNA-seq) revealed a total of
444 genes upregulated and 161 genes downregulated in
NHP iPSC-CMs compared with 288 genes upregulated and
97 genes downregulated in human iPSC-CMs. Among
these genes, only 159 were commonly upregulated and 28
commonly downregulated in the two groups (Table S4).
Further analysis indicates that these genes are responsible
for regulation of glucosemetabolism and post-translational
modification, among other processes (Figure 4A). However,
when evaluating the functions of differentially expressed
genes in the two species, more common pathways were
identified with the functions of promoting cell viability,
cell survival, and glycolysis, as well as in inhibiting cardiac
hypertrophy and fibrosis (Figure 5A). Interestingly, some
pathways that are regulated toward opposite directions be-
tween the two groups aremore related to the fate of connec-
tive tissue cells, fibroblasts, and endothelial cells (Figure 5B).
Using Ingenuity Pathway Analysis (IPA), genes involved
in shared pathways regulating cell survival, angiogenesis
(Figures S2A and S2B), hypertrophy, and fibrosis (Figures
S3A and S3B) are dimensionally divided into nucleus,
cytosol, membrane, and extracellular space according to
the spatial distribution of their encoded proteins. Interest-
ingly, the vascular endothelial growth factor (VEGF) was
significantly elevated in both groups (4.6-fold increase
in NHP iPSC-CMs and 2.7-fold in human iPSC-CMs;
p < 0.01, Figure 4B) and was noted in all four protective
pathways. More importantly, this protein was located
in the extracellular space according to IPA as a secreted fac-
tor. The media collected from the cultured CMs further
proved that VEGF was indeed secreted from both types ofrdial Infarction
n iPSC-CMs were identified with non-specific cardiac troponin T and
ved under 633 magnification.
taining. PBS and fibroblast control groups showed more transmural
ardium.
ic zone and presented as a percentage of the area of ischemic zone.
yocardial area, was compared among PBS and cell-treated groups.
last, n = 6; human iPSC-CM, n = 6 independent experiments. Data
rsus NHP fibroblast; #p < 0.05, ##p < 0.01, NHP iPSC-CM versus PBS;
n iPSC-CM versus PBS.
Figure 3. Myocardial Remodeling Was Compared at Histological Level at Border Zone and Remote Zone to the Infarct
(A) Cardiomyocyte size was compared among PBS, NHP fibroblast, NHP iPSC-CM, human fibroblast, and human iPSC-CM groups.
(B) Examples of wheat germ agglutinin staining showing the size of endogenous mouse cardiomyocytes of the three groups.
(C) Fibrosis was quantified as the percentage of interstitial collagen deposition.
(D) Representative images of Picro-Sirius red staining showing interstitial fibrosis of the three groups.
(E) Capillary density was quantified as absolute number of capillaries per unit area.
(F) Representative CD144 staining showing capillaries.
PBS, n = 5; NHP fibroblast, n = 6; NHP iPSC-CM, n = 6; human fibroblast, n = 6; human iPSC-CM, n = 6 independent experiments. Data
are presented as mean ± SEM. *p < 0.05, **p < 0.01, NHP iPSC-CM versus NHP fibroblast; #p < 0.05, ##p < 0.01, NHP iPSC-CM versus PBS;
yp < 0.05, yyp < 0.01, human iPSC-CM versus human fibroblast; zp < 0.05, zzp < 0.01 human iPSC-CM versus PBS.
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Figure 4. RNA-Seq Analysis of Both NHP and Human iPSC-CMs in Response to 24-hr Oxygen Depletion
(A) The numbers of significantly regulated genes (p < 0.05) and the significant biological function of the common genes in both groups are
listed.
(B) Fold change of VEGF gene in hypoxic iPSC-CMs from both species.
(C) Fold change of VEGF in culture medium using proteomic angiogenesis assay.
n = 3 independent experiments. Data are presented as mean ± SEM. **p < 0.01.
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Figure 5. Comparison of Biological Function Revealed by RNA-Seq Analysis between NHP and Human iPSC-CMs after 24-hr Hypoxia
(A) Common biological functions of the genes.
(B) Biological functions that are regulated toward opposite directions.
n = 3 independent experiments.iPSC-CMs after oxygen depletion (5.0 ± 0.6-fold increase
in NHP iPSC-CMs and 5.4 ± 0.4-fold in human iPSC-CMs;
p < 0.01, Figure 4C).
To understand how these differentially expressed genes
were regulated, we next studied the transcription factors
that bind to the conserved regions of these genes using
the online Database for Annotation, Visualization and In-
tegrated Discovery (DAVID) v6.8. We found that among
the top enriched transcription factors, 25 of them,
including hepatic leukemia factor and insulin-like growth
factor 1 (IGF-1), were shared by both species. Other
transcription factors distinctly appeared in one of the
groups, such as FOXO1 and STAT1 inNHP iPSC-CMs versus
FOXO3 and ATF6 in human iPSC-CMs (Table S5).Metabolic Paracrine Actions from iPSC-CMs after
Oxygen Depletion
To elucidate how paracrine factors secreted from iPSC-CMs
affect the microenvironment through metabolic regula-
tion, we collected culture media from NHP and human
iPSC-CMs at 24 hr after oxygen depletion for metabolo-
mics analysis. A heatmap was generated based on metabo-
lomics data that compared the fold change of the number
of metabolites detected under the hypoxic condition
with those under the normoxic condition (Figure 6A).
The pattern in the heatmap shows that the signatures of
both species are largely similar except for some local differ-
ences. A total of 318 variables/metabolites were retained
in the volcano plot, among which 70 variables in NHPStem Cell Reports j Vol. 10 j 422–435 j February 13, 2018 429
Figure 6. Metabolomic Analysis of the Culture Media in Response to 24-hr Hypoxia
(A) Heatmap generated from metabolomic analysis. Relative expression values (log ratios versus normoxic condition) were used.
(B) Volcano plot of the total and top regulated (p < 0.05) metabolites seen in NHP iPSC-CMs.
(C) Volcano plot of the total and top regulated (p < 0.05) metabolites seen in human iPSC-CMs.
(D) Comparison of the metabolites changed more than 2-fold between the two species.
n = 3 independent experiments.iPSC-CMs (Figure 6B) and 58 in human iPSC-CMs (Fig-
ure 6C) reached statistical difference (p < 0.05). When me-
tabolites that were changed over 2-fold from normoxic
condition between the two groups were plotted, the
slope of the regression line was 0.95, with a coefficient of
determination R2 of 0.78, suggesting the majority of the430 Stem Cell Reports j Vol. 10 j 422–435 j February 13, 2018changes in metabolites were proportional between NHP
and human iPSC-CMs (Figure 6D). Both groups were found
to be involved in regulating ketogenesis, ketolysis, and
methylglyoxal-related metabolism (Figure S4A). However,
metabolites from NHP iPSC-CMs were more involved
in glycogenolysis, whereas the metabolites from human
iPSC-CMs were related to lactose degradation and citric
acid cycle (Figures S4B and S4C).DISCUSSION
Our study compared the similarities and differences be-
tween NHP iPSC-CMs and human iPSC-CMs for treatment
of subacute MI in a rodent model. For clinical relevance,
rather than using permanent coronary artery ligation as
used by previous studies (Citro et al., 2014; Lepperhof
et al., 2014; Ong et al., 2015), we utilized the ischemia-
reperfusion model to simulate MI patients with re-estab-
lished blood supply after intervention. In addition, instead
of acute treatment within 24 hr after MI (Carpenter et al.,
2012; Lepperhof et al., 2014; Ong et al., 2015), we injected
cells at day 4 post infarction, which is the subacute stage of
MI, to simulate the delay for iPSC-CM match and prepara-
tion for cell transplantation. After cell injection, both NHP
and human iPSC-CM groups showed similar improvement
in LV contractility at 2 weeks post transplantation, and this
improvement was preserved at week 4. Furthermore, both
echocardiography and hemodynamic analysis demon-
strate the improvement in both systolic and diastolic func-
tion as shown by LVEF and tau. To prove that such an effect
is specific to iPSC-CMs, we analyzed a separate negative
cohort with functionally unrelated NHP or human fibro-
blasts. Similar to previous studies (Kolossov et al., 2006;
Yeghiazarians et al., 2012), during the 4-week period after
cell delivery, fibroblast-treated groups did not alter cardiac
function, and severe LV chamber dilatation was observed
at the end of the 4-week period. It is worth noting that
while the end-diastolic volume continuously increased
after cell transplantation in the control groups, the end-
systolic volume was markedly reduced in both iPSC-CM-
treated groups. This continual dilatation and remodeling
in end-diastolic volume may represent a compensatory
mechanism in response to increased wall stress (Grossman,
1980). In previous studies using iPSC-CMs from different
species, the changes in LV function varied from study to
study (Citro et al., 2014; Wu et al., 2016). In our current
study, both NHP and human iPSC-CMs showed similar
potency in improving LV function and attenuation in
chamber dilatation.
This similarity in functional improvement was accom-
panied by similar changes at the histological levels in
both NHP and human iPSC-CMs. We noted that within
the ischemic zone, the total viable tissues (composed of
grafts and host myocardium) were present to a similar
extent between the two iPSC-CM-treated groups. In addi-
tion to the increased viable tissue and reduced scar size,
we noted a smaller cardiomyocyte size and less interstitial
fibrotic tissue in both iPSC-CM-treated groups at both BZand RZ. This indicates a similar attenuation in remodeling
with less hypertrophy and less reactive fibrosis. Moreover,
consistent with previous studies showing angiogenesis in
the iPSC-CM-treated MI hearts (Lepperhof et al., 2014;
Ye et al., 2014), we also found that the capillary density
was similarly increased in both iPSC-CM-treated groups
at the BZ and RZ. Although the total amount of grafts
was difficult to quantify accurately at 4 weeks after cell
transplantation, we observed that a small amount of grafts
exist at different sections of the LV wall in both iPSC-CM-
treated groups. They presented as either free cells or clus-
ters at the ischemic zone and BZ, but there was no sign
of remuscularization or contact between engraftment
and host myocardium as reported in other studies (Chong
et al., 2014; Shiba et al., 2016). Therefore, the improved
function was not directly due to the engraftment in the
ischemic zone. Comparing the size of the grafts with the
whole LV wall, it is reasonable to infer that paracrine
effects of iPSC-CMs play a pivotal role in maintaining car-
diac function and attenuating myocardial remodeling.
Indeed, numerous studies have shown that adult stem
cells and their derived cells affect the microenvironment
via paracrine actions (Mirotsou et al., 2007; Ong et al.,
2015; Ye et al., 2015).
To further understand post-transplantation response of
the graft to the host ischemic myocardium, we simulated
the oxygen-depletion condition the grafts encountered
in vivo, and compared the transcriptomic andmetabolomic
profiles of both iPSC-CMs in vitro. Given the species differ-
ence, it was not surprising to see certain differences in the
iPSC-CMs at the molecular level. Among all genes that
were significantly up- or downregulated, RNA-seq revealed
only a small portion of shared genes between NHP and hu-
man iPSC-CMs. Despite few overlapping genes, we noted
that many biological functions were regulated similarly
toward the same direction. This finding suggests that in
addition to using some of the shared genes, NHP and hu-
man iPSC-CMs utilized different sets of genes to achieve
the same in vivo outcomes. For instance, along with a
similar increase in capillary density in vivo, the RNA-seq
showed a comparable upregulation in VEGF and angioge-
nin. However, IGF receptor (Bid et al., 2012) was signifi-
cantly upregulated only in NHP iPSC-CMs, whereas
platelet-derived growth factor (Moriya et al., 2014) was up-
regulated more in human iPSC-CMs. These phenomena
also applied to the genes promoting cell survival and inhib-
iting fibrosis and hypertrophy (Figures S2 and S3), as well as
transcription factors that are involved in cardioprotection
(Table S5). Although in vivo analysis showed that the pro-
tection against MI was similar between the two groups,
RNA-seq and pathway analysis revealed that fewer genes
were involved in these related pathways in human iPSC-
CMs compared with NHP iPSC-CMs. Transcription factorsStem Cell Reports j Vol. 10 j 422–435 j February 13, 2018 431
that control these genes were changed more dramatically
in NHP iPSC-CMs (Table S5).
We also found that some pathways were differentially
activated between NHP and human iPSC-CMs, indica-
ting a species-specific response to hypoxia. Interestingly,
VEGF was found to be upregulated in both NHP and
human iPSC-CMs. VEGF is implicated in all four cardiopro-
tective biological functions, promoting cell survival and
angiogenesis as well as inhibiting hypertrophy and fibrosis.
Based on IPA, the VEGF gene encodes a protein that will be
eventually secreted to extracellular space. Indeed, proteo-
mic analysis of the culture media after oxygen depletion
also showed an increased VEGF level. VEGF has been
demonstrated by several studies to confer benefits to the
ischemic heart (Byrne et al., 2005; Hoeben et al., 2004;
Park et al., 2009; Xu et al., 2011). Although gene therapy
for MI with VEGF failed in clinical trials (Kastrup et al.,
2005; Stewart et al., 2009), its contribution to cardioprotec-
tion cannot be excluded.
In addition to VEGF, we also found other hypoxia-
induced differentially expressed genes shared by both
NHP and human iPSC-CMs. Jumonji domain-containing
protein 6 (JMJD6) is an arginine demethylase known to
demethylate histone H3 at arginine 2 and histone H4 at
arginine 3 (Chang et al., 2007) and found to be upregulated
in hypoxia-treated cardiomyocytes in our RNA-seq data.
Previous reports have shown that JMJD6 regulates RNA
splicing through modification of splicing factor U2 small
nuclear ribonucleoprotein auxiliary factor 65-kDa subunit
(Webby et al., 2009) and is required in endothelial cells to
regulate the splicing of VEGF receptor as well as angiogenic
sprouting (Boeckel et al., 2011). Despite its expression
in cardiomyocytes as shown by immunostaining (Human
Protein Atlas, www.proteinatlas.org), the specific role
of JMJD6 in cardiomyocytes under hypoxia condition is
not known and may require additional investigation.
Moreover, we found some genes to be downregulated by
hypoxia in both NHP and human iPSC-CMs, including
MYB Proto-Oncogene Like 2 (MYBL2), also known as
B-MYB. MYBL2 is a cyclin-dependent kinase and has
been shown to activate genes during the S phase of the
cell cycle (Joaquin and Watson, 2003). It is unclear how
the downregulation of MYBL2 facilitates the ischemic
response of cardiomyocytes, but downregulation of the
cell cycle has been shown to protect cells from DNA dam-
age or ischemia-induced cell death (Nowsheen and Yang,
2012). Taken together, our RNA-seq data suggest common
pathways for both NHP and humna iPSC-CMs in response
to ischemia.
Themetabolomic profile of the two types of iPSC-CMs in
response to oxygen depletion was another parameter we
examined in comparing the two species. Unlike changes
in the transcriptomic profile in which a small number432 Stem Cell Reports j Vol. 10 j 422–435 j February 13, 2018of common genes were shared between the two species,
the changes in secreted metabolites were much more
alike. This similarity existed not only in the direction
of the changes but also in the extent of the changes of
individual metabolites (Figure 6D). In examining the
top changed metabolic pathways, we noted, along with
certain similarities between the two species, that there
were more regulated pathways unique to one species (Fig-
ures S4B and S4C).
One potential limitation of our study is the absence of a
large animalmodel due to prohibitive costs (e.g., transplan-
tation of NHP or human iPSC-CMs into NHP). Allogeneic
transplantation with rodent iPSC-CM is also an option.
However, current protocols do not allow for the generation
of rat or mouse iPSC-CMs at a sufficient amount and purity
level (Liao et al., 2009; Liu et al., 2013; Merkl et al., 2013;
Takenaka-Ninagawa et al., 2014; Yamaguchi et al., 2014).
Nevertheless, our observation of comparable improve-
mentwith either NHP or human iPSC-CMs in a xenogeneic
rodent model allows an objective comparison between
these two species. Using the current model we could
normalize confounding factors such as rejection and
arrhythmia, thus creating no bias against either NHP or
human iPSC-CM transplantation. Finally, our experiments
provide additional information regarding functional, tran-
scriptomic, and metabolomic changes between NHP and
human iPSC-CMs that may lead to better preclinical study
designs in the future.
Our study provides the cross-species comparison of iPSC-
CMs for the treatment ofMI in a xenogeneic rodentmodel.
Given the phylogenetic distance between human and rhe-
sus (23.3 million years) (Kumar and Hedges, 1998), it is not
surprising to observe differences and similarities when
comparing NHP with human iPSC-CMs. Although the
therapeutic efficacy in vivo and common pathways in vitro
between the two types of iPSC-CMswere very similar, there
were nevertheless differences at the transcriptomic and
metabolomic levels. Future plans to study individual genes
or metabolic pathways in NHP iPSC-CMs for predicting
outcome in human iPSC-CMs should proceed with caution
due to these differences, the exact significance of which
awaits further investigation.EXPERIMENTAL PROCEDURES
For an extended description of methods, please refer to Supple-
mental Experimental Procedures.
Culture and Maintenance of NHP and Human iPSCs
Fibroblasts from a rhesus macaque monkey and healthy male
human donor were reprogrammed into iPSCs via Sendai virus vec-
tors carrying the Yamanaka reprogramming factors (Oct4, Sox2,
Nanog, and cMyc). Both NHP and human iPSCs were grown to
90% confluence (Lan et al., 2013; Sun et al., 2009) on Matrigel-
coated plates (ES Qualified, BD Biosciences, San Diego, CA) using
a chemically defined E8 medium as previously described (Chen
et al., 2011). The medium was changed daily, and cells were
passaged every 3–4 days with EDTA (Thermo Fisher Scientific, CA).
Cardiac Differentiation
Both NHP and human iPSCs were grown to 90% confluence and
subsequently differentiated into beating cardiomyocytes as previ-
ously described (Ebert et al., 2014; Liang et al., 2016). In brief, on
day 0 cells were supplemented with a basal medium (RPMI 1640
[Thermo Fisher Scientific] and 2% B27 supplement minus insulin
[Thermo Fisher Scientific]), with the addition at a concentration
of 2–8 mMof CHIR-99021 [Selleck Chemicals], a selective inhibitor
of glycogen synthase kinase 3b, which activates the canonicalWnt
signaling pathway. On day 2, the mediumwas replaced with basal
mediumwithout CHIR99021 supplementation. On day 3, 5 mMof
IWR-1 [Selleck Chemicals], a Wnt antagonist, was added to basal
medium for 2 days. On day 5 and every subsequent other day until
harvest, the medium was replaced with fresh basal medium.
Cell Transplantation
Four days after reperfusion, animals were randomly grouped into
five groups: (1) 13 107 NHP iPSC-CMs (n = 14), (2) 13 107 human
iPSC-CMs (n = 14), (3) 13 PBS (n = 14), (4) 1 3 107 human fibro-
blast (n = 9), and (5) 1 3 107 NHP fibroblast (n = 9). The chest
was reopened and cells or PBS were injected intramyocardially at
2–3 sites along the edge of the infarct zone with a total volume
of 70 mL with a 28-gauge insulin syringe. Study protocols were
approved by the Stanford Animal Research Committee. Animal
care was provided in accordance with the Stanford University
School ofMedicine guidelines and policies for the use of laboratory
animals.
Echocardiography
At 1 day before injection, and 2 and 4weeks after injection, cardiac
functionwas assessed using transthoracic echocardiography (Vevo
2100 Imaging System, VisualSonics). Animals were anesthetized
with 2% inhaled isoflurane, and LV internal dimensions were
measured in systole and diastole using leading-edge methods and
guidelines of the American Society of Echocardiography (Sahn
et al., 1978). LV systolic function was estimated using the Vevo
Lab software for calculation.
In Vitro Oxygen Depletion Treatment
At 30 days after differentiation, 33 106NHP iPSC-CMs and 33 106
human iPSC-CMs were collected and replated onto Matrigel-
coated 6-well plates. Culture media were changed every 2 days
for 5 days. On day 5, half of the plates were placed in an anaerobic
pouch (GasPak EZ Anaerobe Pouch System, Fisher Scientific, MA)
without changing culture media and the other half were left un-
touched. The pouch was sealed with an anaerobic indicator. The
color of indicator changed to blue for the anaerobic conditions.
Cells were incubated for another 24 hr before media from both
hypoxic and normoxic iPSC-CMs were collected for proteomic
VEGF analysis. Cells were collected for transcriptomic profile
analysis.RNA Sequencing
Kits used for RNA-seq were purchased from Thermo Fisher. Total
RNAwasmixedwithERCCRNASpike-InMix1andpolyadenylated
mRNAwas isolated using the DynabeadsmRNADIRECTMicro Pu-
rificationKit. A cDNA librarywas preparedusing the IonTotal RNA-
seq Kit v2 and sequenced by the Ion Proton using Ion PI Hi-Q
Sequencing kit. Unaligned BAM files were generated by the Ion
Torrent Suite 5.0.4 and converted into FASTQ files. The reads for
three replicates for human or NHP iPSC-CMs, with or without oxy-
gen depletion,weremapped to reference genomehg19 (human) or
rheMac8 (NHP) using TopHat (v2.0.13), assembled with Cufflinks
(v2.2.1), and differentially expressed genes induced by oxygen
depletion treatment were identified by Cuffdiff (v2.2.1). Because
the rhesusmacaque genome is notwell annotated, humangenome
(RefSeq Genes) and the rhesus macaque genome were aligned for
annotation, resulting in the same gene IDs for both human and
rhesus macaque. Molecular pathways and disease or toxicological
functions of differentially expressed genes (false discovery rate
<0.05, log ratio >1.5) were analyzed by IPA (Qiagen).Statistical Analysis
Data are expressed as mean ± SEM. Statistical significance was
determined using Student’s t test or ANOVA test evaluations.
p < 0.05 was taken as a minimal level of significance.ACCESSION NUMBERS
The accession number for the raw and processed data from the
RNA-seq experiments reported in this paper is GEO: GSE108676.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, four figures, and five tables and can be found with
this article online athttps://doi.org/10.1016/j.stemcr.2018.01.002.
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